Lifty

Quick links to important sections

Lifty

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lifty

Understanding Lifty

Lifty is a therapeutic option developed to address specific physiological needs within its indicated therapeutic area. As a pharmacological intervention, it is designed to interact with biological pathways to manage or alleviate symptoms associated with certain medical conditions.

Mechanism and Purpose

The primary function of Lifty involves the modulation of specific internal processes. By targeting these pathways, the medication aims to stabilize or improve the clinical status of the individual. Its development is rooted in clinical research aimed at providing a consistent response for those diagnosed with relevant conditions.

Clinical Role

Lifty is utilized within a broader management plan. Its role is characterized by its influence on the underlying biological mechanisms of a condition rather than serving as a temporary surface-level solution. Healthcare providers consider various factors, including the individual's overall health profile and the specific nature of their condition, when determining the place of this medication in a longitudinal care strategy.

Characteristics

  • Therapeutic Intent: Designed for long-term or acute management depending on the specific medical requirement.
  • Formulation: Developed to ensure the active components are delivered effectively to the intended biological sites.
  • Application: Used in clinical settings to support patient health objectives through targeted pharmacological action.

Regulatory References

  1. Phosphodiesterase Type 5 (PDE5) Inhibitors - LiverTox - NIH
  2. Sildenafil: MedlinePlus Drug Information

What side effects are possible with Lifty?

Possible Side Effects and Safety Information for Lifty

Adverse reactions associated with Lifty, as documented in regulatory sources, are categorized by frequency and the affected body system (System Organ Class).

Serious and Clinically Significant Adverse Reactions

Official labeling for Lifty includes Boxed Warnings (or similar prominent regulatory warnings) to highlight the most serious or life-threatening risks. Clinically significant adverse reactions requiring particular caution include the potential for acute pancreatitis and risk of non-arteritic anterior ischaemic optic neuropathy (NAION). Additionally, gastrointestinal adverse reactions may lead to dehydration, which in rare cases can potentially result in a deterioration of renal function. A known contraindication to the use of Lifty is a documented history of hypersensitivity to the active substance or any of its excipients.


Common Adverse Reactions

The most frequent adverse events observed in clinical trials, typically classified as Very Common (ge 1/10) or Common (ge 1/100 to < 1/10), primarily involve the Gastrointestinal System. These commonly reported effects may include nausea, vomiting, diarrhea, constipation, and abdominal pain.

Other adverse reactions from various System Organ Classes, such as Nervous System Disorders (e.g., headache) and General Disorders (e.g., fatigue), are also reported in a structured list by frequency.


Population-Specific Safety Considerations

Safety data for Lifty necessitates specific considerations for certain patient groups, with adjustments recommended for individuals with severe renal impairment or severe hepatic impairment, where the drug is generally not recommended due to limited experience and altered elimination profiles. Furthermore, safety and efficacy have not been established in children below 12 years of age, and caution is advised during general anesthesia or deep sedation due to the risk of delayed gastric emptying and potential pulmonary aspiration.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for sildenafil (Lifty) states that overexposure primarily leads to an increased incidence and severity of known effects. Overdose manifestations documented in regulatory sources include severe headache, intense flushing, dyspepsia (indigestion), and significant hypotension (decreased blood pressure).


Official Guidance on Severe Outcomes and Emergency Action

Severe Outcome Documented in Labeling Regulator-Mandated Action
Erection persisting longer than four hours Seek immediate medical assistance to prevent permanent penile tissue damage or loss of potency.
Sudden loss of vision in one or both eyes Seek prompt medical attention immediately.
Sudden decrease or loss of hearing Seek prompt medical attention immediately.

Overdose management is specified as symptomatic and supportive treatment, with no specific antidote known. Close monitoring of cardiovascular status and blood pressure is required due to the vasodilatory effects. Regulatory documents note that because sildenafil is highly protein bound, dialysis is unlikely to significantly aid in clearance. Exposure risk is heightened for patients with severe renal or hepatic impairment due to reduced drug clearance.

Therapeutic Uses of Lifty

What Lifty Treats: Main Uses and Benefits

Lifty, containing Sildenafil, is commonly used across two distinct therapeutic domains to provide functional and symptomatic support for symptoms linked to organ-specific functional stress. The medication is relevant for both erectile dysfunction (ED) and pulmonary arterial hypertension (PAH).


Therapeutic Contexts and Symptom Relief

The medication is applied in addressing two major categories of conditions: those involving functional deficits in erection and conditions marked by symptoms that interfere with daily functioning, such as limited exercise tolerance in the lungs. It helps address symptom clusters that interfere with daily comfort and may assist with maintaining functional stability. For adult men, the primary benefit is support for maintaining functional stability in cases of impaired erectile function. For patients, including adults and children, with PAH, it is commonly used to help with challenging manifestations like shortness of breath, fatigue, and dizziness. This supportive therapy contributes to easing the symptom burden during daily physical activities.

Quick Fact: Supportive Assistance for Exertional Dyspnea and Impaired Rigidity

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Lifty (Sildenafil) is approved for use in specific adult populations and pediatric patients (aged 1 to 17 years for pulmonary arterial hypertension). Eligibility is strictly defined by regulatory contraindications and restrictions.

Absolute Contraindications

Use is formally prohibited for patients taking organic nitrates or riociguat. It is also contraindicated for individuals with a known hypersensitivity to the drug, a history of vision loss from NAION, severe hepatic impairment (Child-Pugh Class C), severe resting hypotension (BP < 90/50 mmHg), or a recent history of stroke or myocardial infarction.

Age and Physiological Restrictions

The medicine is not indicated for individuals under 18 years for the treatment of erectile dysfunction, and its safety is not established in infants under 1 year of age. Caution is required for older adults, as well as patients with severe renal impairment or mild-to-moderate hepatic impairment, which may necessitate special consideration.

Restricted Use and Special Populations

Use is not recommended in patients with Pulmonary Veno-Occlusive Disease (PVOD). Caution is also advised for patients with anatomical deformation of the penis (e.g., Peyronie's disease) or conditions predisposing to priapism (e.g., sickle cell anemia). For pregnant and breastfeeding women, adequate human study data are limited, precluding a clear determination of risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official interaction profile for Lifty (Sildenafil) as documented in government regulatory prescribing information.


Formally Documented Contraindicated Combinations

Co-administration of Lifty is strictly prohibited (contraindicated) with the following substances due to the documented risk of severe hypotension stemming from a potentiation of effects:

  • Organic Nitrates (e.g., Nitroglycerin, Isosorbide Dinitrate) in any form.
  • Guanylate Cyclase (GC) Stimulators (e.g., Riociguat).

Pharmacokinetic and Pharmacodynamic Interaction Categories

Interaction Type Interacting Substance/Class Official Regulatory Statement
Increased Exposure Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) Significantly increase Sildenafil plasma exposure (AUC and Cmax) by reducing metabolic clearance.
Decreased Exposure CYP3A4 Inducers (e.g., Bosentan) Officially documented to decrease Sildenafil plasma exposure by accelerating metabolism.
Additive Effects Alpha-Blockers (e.g., Doxazosin) May cause symptomatic hypotension due to additive blood pressure lowering effects.
Food Interaction High-Fat Meal Documented to delay the time to maximum concentration (Tmax) and reduce the maximum concentration (Cmax) of Sildenafil.

Co-administration with other PDE5 inhibitors is not recommended, as the safety and efficacy of these combinations have not been established in regulatory studies.

Mechanism of Action

The mechanism of Sildenafil involves selective enzyme inhibition that modulates a natural signaling pathway. The drug strictly targets the biology of cGMP signaling to modulate vascular smooth muscle tone.


Selective Inhibition of the PDE5 Enzyme

The primary action is the selective inhibition of Phosphodiesterase type 5 ( PDE5), an enzyme responsible for hydrolyzing the signaling molecule cyclic Guanosine Monophosphate ( cGMP). By blocking PDE5, the drug prevents cGMP from being destroyed, thereby increasing its concentration within the target cells. This enzyme-inhibition domain is the molecular basis for the drug's downstream effects.


Modulating the NO- cGMP Signaling Pathway

The rise in cGMP levels activates a cascade that ultimately leads to the relaxation of vascular smooth muscle. This mechanism is critically dependent on the body's natural release of Nitric Oxide ( NO), as Sildenafil only acts to sustain the cGMP signal, not as a signal initiator. This process of smooth muscle relaxation results in localized vasodilation (vessel widening), which is the principal physiological consequence of the mechanism.


Mechanistic Limitations and Specificity

Sildenafil's action is fundamentally constrained by the requirement of prior NO release; without the initial physiological trigger, the mechanism is functionally irrelevant. Furthermore, while highly selective for PDE5, the drug exhibits a minor, non-selective inhibitory effect on PDE6 in the eye, which is a known mechanistic limitation affecting visual phototransduction.

Dosage and Administration Information

Official Administration Routes and Regimens

Lifty, which contains Sildenafil, is primarily administered via the oral route using tablets, film-coated tablets, or a reconstituted oral suspension. An intravenous (IV) route is also an approved option for patients with pulmonary arterial hypertension who are temporarily unable to take the oral formulation.

Official dosing schedules are distinct for each approved indication, defining whether the use is continuous or intermittent.

Indication Administration Pattern Dosing Schedule Maximum Frequency
Erectile Dysfunction (ED) As-needed (Intermittent) Starting dose is 50 mg (range: 25 mg to 100 mg) Once per day
Pulmonary Arterial Hypertension (PAH) Scheduled (Continuous) 20 mg taken three times a day (TID) 4 to 8 hours apart

For the treatment of PAH, the 20 mg dose may be increased up to 80 mg TID in certain circumstances. The IV form is administered as a 10 mg bolus injection when temporarily substituting the oral dose.

Administration Conditions and Adjustments

Tablets may be taken with or without food. Taking a dose with a high-fat meal may delay the onset of activity. The oral suspension formulation must be reconstituted with water to achieve the correct concentration before use. For the ED indication, a lower starting dose of 25 mg is often considered for older adults, as well as patients with severe renal or hepatic impairment. Procedurally, patients receiving Sildenafil for PAH are restricted from simultaneously taking any other Sildenafil product or other Phosphodiesterase 5 (PDE5) inhibitors to prevent unintended dose overlap.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lifty (Sildenafil)

Evidence for Use in Erectile Dysfunction

Research exploring the use of Lifty for adult men with erectile dysfunction (ED) relies heavily on randomized controlled trials (RCTs). These studies included adult men who had ED, often with underlying conditions like diabetes mellitus. Researchers measured functional endpoints related to the ability to attain and maintain an erection using patient-reported outcomes. Findings describe patterns where measured changes in these functional endpoints differed between the compound and placebo groups. The research noted that stimulation was necessary for the measures of effect to be recorded in the trials. Evidence for the sustained nature of the reported outcomes over many years is limited.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Core evidence for Lifty in adult PAH, a condition marked by functional limitations, comes from placebo-controlled RCTs. Research examined measures of exercise capacity, primarily the 6-Minute Walk Distance (6MWD), and monitored changes in blood flow dynamics. Studies reported that adult patients receiving the active compound had higher average measurements in their 6MWD compared to placebo.

The initial pivotal trials were designed to primarily assess functional outcomes rather than overall survival. Therefore, evidence for long-term effects on core physiological strain and sustained hemodynamic measurements is not fully established.

Specific Research Considerations for Pediatric PAH

Research was conducted on pediatric patients (children aged 1 to 17 years) with PAH. Studies show patterns related to an unexpected signal of increased mortality risk that was associated with chronic use of higher doses of the medication in children. This observation led major regulatory bodies to issue formal cautionary statements. The interpretation of the evidence in this group appears uncertain, and certainty remains low for chronic, high-dose use in pediatric patients.

Frequently Asked Questions (FAQ)

Common questions about Lifty (FAQ)


Q: How quickly do most people notice any effects from Lifty?

According to official product information, the onset of activity for the treatment of ED is typically observed within 30 minutes to one hour after administration. The duration of the therapeutic window described in official labeling is up to 4 hours.


Q: Are there any foods or drinks I should avoid while using Lifty?

Regulatory documents note that alcohol may increase the risk of symptoms related to lowered blood pressure, such as dizziness. Additionally, the ingestion of large amounts of grapefruit juice may increase the body's exposure to the medication.


Q: Are there any long-term effects of using Lifty that I should know about?

Official research evidence describes limitations in the study of sustained therapeutic outcomes over many years. The long-term safety profile is subject to ongoing analysis through mandatory post-marketing surveillance by regulatory bodies.


Q: Can Lifty be taken if a person has diabetes?

Clinical trials for the use of Lifty in erectile dysfunction included individuals with underlying conditions, such as diabetes mellitus. Official guidance states that the underlying cardiovascular status of the patient should be considered before starting treatment.


Q: Why do people sometimes say Lifty didn't work for them?

The medication relies on sexual stimulation to facilitate its expected effect; without stimulation, the biological action is not triggered. Official instructions also indicate that taking the medication with a high-fat meal may delay the onset of activity.


Q: Is the research evidence for Lifty considered strong?

The primary evidence supporting the approved uses comes from placebo-controlled randomized clinical trials (RCTs). Regulatory documents note that while these trials demonstrate effect, evidence for long-term survival and sustained therapeutic outcomes is not fully established.


Q: What is the pregnancy safety classification for Lifty?

Official regulatory information describes the available data in pregnant women as limited. This restricts a definitive determination of drug-related risk during pregnancy.


Q: How is the long-term safety of Lifty studied?

Long-term safety is managed by regulatory agencies primarily through mandatory post-marketing surveillance and pharmacovigilance programs. These systems collect and analyze data on adverse events from patients globally after the drug has been made publicly available.


Q: What happens if I forget to take Lifty?

For conditions requiring continuous treatment (PAH), official guidance describes taking the next scheduled dose and not taking two doses together. For the as-needed treatment (ED), a dose is only taken when required.


Q: Does Lifty cause weight gain or weight loss?

Weight gain or weight loss are not listed among the commonly reported or clinically significant adverse reactions in the official regulatory documents.


Q: Is Lifty safe to use if I have high blood pressure?

Official documents do not list pre-existing high blood pressure (hypertension) as a formal contraindication. Regulatory information indicates that patients' blood pressure status should be considered as part of a risk assessment prior to use.


Q: Can Lifty affect my ability to drive or operate machinery?

Official labeling notes that formal studies on the effects on the ability to drive or use machines have not been performed. Side effects such as dizziness and visual changes have been reported, which could potentially affect the ability to perform these activities.


Q: Can I use Lifty if I am already taking herbal supplements?

Regulatory guidance states that the safety and effectiveness of taking the medication alongside specific herbal remedies and supplements have not been established. This is because these products are not typically tested in the same way as prescription medications.


Q: How long does it usually take for Lifty to be completely out of my system?

The active ingredient's half-life—the time required for half the dose to leave the body—is approximately 3 to 4 hours. Based on this pharmacokinetic data, elimination of the medication is typically expected within one day after the last dose.


Q: Can Lifty be crushed or split if it is hard to swallow?

The tablets are supplied as a whole, specific dosage form, and official labeling does not typically include instructions for crushing or splitting them. For patients who have difficulty swallowing, an oral suspension (liquid) formulation is available.


Q: Is there a generic version of Lifty available?

The active ingredient in Lifty, Sildenafil, is available as a generic product. This generic status is listed in official records maintained by government bodies like the FDA.


Q: Is Lifty habit-forming or addictive?

The active ingredient in Lifty is not listed in the US Controlled Substances Act (CSA) schedule. Official documents, therefore, do not typically define the medication as a substance that is habit-forming or addictive.


Q: What if I experience a rare but serious side effect from Lifty?

The official patient information emphasizes the need to seek immediate medical attention if certain serious adverse reactions are experienced. Examples of serious events include chest pain, sudden loss of vision, or an erection lasting longer than 4 hours.


Q: Does Lifty change the way my body handles alcohol?

Official documents state that alcohol may increase the blood pressure-lowering effect of the medication, which can lead to symptoms like dizziness or lightheadedness. Limiting alcohol consumption while using the drug is generally described as appropriate.


Q: Does Lifty affect sleep patterns?

Official adverse reaction reports include sleep problems, such as insomnia, among the documented side effects of the medication. This is listed as an effect on the nervous system.


Q: Where can I find the official patient information leaflet for Lifty?

The official Patient Information Leaflet (PIL) can typically be located on the websites of government drug regulatory agencies, such as the FDA (DailyMed) or the EMA (SmPC). Searching for the active ingredient, Sildenafil, is often the recommended way to find it.


Q: What should I do if I am taking Lifty and plan to have surgery?

Due to the medication's known effects on blood pressure, regulatory documents indicate that the use of this drug should be reported to medical staff when planning any procedure or surgery. This is especially important for procedures requiring general anesthesia or deep sedation.

How should Lifty be stored and disposed of?

Lifty (Sildenafil) must be stored under specific conditions to maintain product stability and must be kept out of the reach of children.

Requirement Official Labeled Condition
Storage Temperature Store tablets at 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Container Protection Keep the medication in its original package, with the container tightly closed, to protect from moisture.
Stability Limit The reconstituted oral suspension must be discarded 60 days from the date of reconstitution; do not freeze.
Disposal Unused or expired product must be disposed of in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lifty found in:

A-Z Index: